2 weeks Ago By ABMN Staff
Federated Hermes Inc. acquired a new position in CG Oncology, Inc. ( NASDAQ:CGON – Free Report ) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission.
The firm acquired 6,000 shares of the company’s stock, valued at approximately $172,000. A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Wellington Management Group LLP lifted its stake in CG Oncology by 274.
4% during the 4th quarter. Wellington Management Group LLP now owns 1,910,470 shares of the company’s stock valued at $54,792,000 after acquiring an additional 1,400,251 shares during the period. Vanguard Group Inc.
boosted its holdings in CG Oncology by 15.3% in the fourth quarter. Vanguard Group Inc.
now owns 5,861,082 shares of the company’s stock valued at $168,096,000 after purchasing an additional 779,730 shares during the last quarter. Alliancebernstein L.P.
grew its position in CG Oncology by 61.6% during the 4th quarter. Alliancebernstein L.
P. now owns 1,817,887 shares of the company’s stock worth $52,137,000 after purchasing an additional 692,982 shares during the period. Pictet Asset Management Holding SA purchased a new position in shares of CG Oncology during the 4th quarter valued at about $19,348,000.
Finally, Geode Capital Management LLC lifted its holdings in shares of CG Oncology by 96.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,078,527 shares of the company’s stock valued at $40,701,000 after buying an additional 528,749 shares during the period.
Institutional investors and hedge funds own 26.56% of the company’s stock. CG Oncology Price Performance Shares of CG Oncology stock opened at $20.
64 on Friday. The stock has a market capitalization of $1.57 billion, a P/E ratio of -14.
54 and a beta of 1.24. The business has a 50 day simple moving average of $24.
32 and a two-hundred day simple moving average of $29.81. CG Oncology, Inc.
has a 12 month low of $14.80 and a 12 month high of $46.99.
Analyst Upgrades and Downgrades CGON has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $75.00 price target on shares of CG Oncology in a research report on Monday, March 31st.
Morgan Stanley reiterated an “overweight” rating and issued a $55.00 target price on shares of CG Oncology in a research note on Friday, March 7th. TD Cowen began coverage on shares of CG Oncology in a research report on Tuesday, January 7th.
They set a “buy” rating on the stock. Finally, Scotiabank initiated coverage on shares of CG Oncology in a research report on Wednesday. They issued a “sector perform” rating and a $23.
00 price objective for the company. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.
com, CG Oncology has a consensus rating of “Buy” and a consensus price target of $59.33. Check Out Our Latest Stock Analysis on CGON CG Oncology Company Profile ( Free Report ) CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer.
The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. Recommended Stories Want to see what other hedge funds are holding CGON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CG Oncology, Inc.
( NASDAQ:CGON – Free Report ). Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter .
.
